Trial Profile
NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab (MEDI4736) and Tremelimumab in Muscle-invasive Urothelial Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 12 Mar 2024
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Doxorubicin (Primary) ; Durvalumab (Primary) ; Methotrexate (Primary) ; Tremelimumab (Primary) ; Vinblastine (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms NEMIO
- 05 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 24 Oct 2023 Results (n=121, cut off date : between November 2018 and April 2022) presented at the 48th European Society for Medical Oncology Congress.
- 21 Apr 2022 Planned number of patients changed from 120 to 121.